CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY. (June 2017) - Klanova, M.; Sehn, L.H.; Bence‐Bruckler, I.; Cavallo, F.; Jin, J.; Martelli, M.; Stewart, D.; Vitolo, U.; Zaja, F.; Zhang, Q.; Mattiello, F.; Oestergaard, M.Z.; et al.